ATE194916T1 - Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren - Google Patents

Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren

Info

Publication number
ATE194916T1
ATE194916T1 AT93910957T AT93910957T ATE194916T1 AT E194916 T1 ATE194916 T1 AT E194916T1 AT 93910957 T AT93910957 T AT 93910957T AT 93910957 T AT93910957 T AT 93910957T AT E194916 T1 ATE194916 T1 AT E194916T1
Authority
AT
Austria
Prior art keywords
treatment
methods
lesions
intravascular
intraoperative
Prior art date
Application number
AT93910957T
Other languages
English (en)
Inventor
David M Goldenberg
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE194916T1 publication Critical patent/ATE194916T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
AT93910957T 1992-05-06 1993-05-06 Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren ATE194916T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87985792A 1992-05-06 1992-05-06
PCT/US1993/004098 WO1993021940A1 (en) 1992-05-06 1993-05-06 Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy

Publications (1)

Publication Number Publication Date
ATE194916T1 true ATE194916T1 (de) 2000-08-15

Family

ID=25375024

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910957T ATE194916T1 (de) 1992-05-06 1993-05-06 Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren

Country Status (7)

Country Link
US (1) US5716595A (de)
EP (1) EP0643583B1 (de)
JP (1) JPH08500335A (de)
AT (1) ATE194916T1 (de)
CA (1) CA2133580A1 (de)
DE (1) DE69329112T2 (de)
WO (1) WO1993021940A1 (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
CA2154667A1 (en) * 1993-02-02 1994-08-18 Linda M. Gustavson Directed biodistribution of small molecules
US5657759A (en) 1993-05-13 1997-08-19 Synectics Medical, Incorporated Measurement of gastric emptying and gastrointestinal output
GB2285862B (en) * 1994-01-22 1998-01-28 Anant Sharma Antibody for the detection of the corresponding antigen in vivo in the diagnosis of disease
US7255851B2 (en) 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US7179222B2 (en) 1996-11-20 2007-02-20 Olympus Corporation Fluorescent endoscope system enabling simultaneous achievement of normal light observation based on reflected light and fluorescence observation based on light with wavelengths in infrared spectrum
US6293911B1 (en) * 1996-11-20 2001-09-25 Olympus Optical Co., Ltd. Fluorescent endoscope system enabling simultaneous normal light observation and fluorescence observation in infrared spectrum
US6562589B1 (en) * 1997-06-17 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services AIB1, a novel steroid receptor co-activator
US6418338B1 (en) 1998-02-06 2002-07-09 Phylatron Ltd. Method for detecting and surgically removing lymphoid tissue involved in tumor progression
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US8114006B2 (en) * 1998-10-06 2012-02-14 University Of South Florida Radio guided seed localization of imaged lesions
US6496717B2 (en) * 1998-10-06 2002-12-17 University Of South Florida Radio guided seed localization of imaged lesions
US20040047804A1 (en) * 1998-10-29 2004-03-11 The General Hospital Corporation, A Massachusetts Corporation Enhanced radiation therapy
US6369918B1 (en) 1999-02-08 2002-04-09 National Semiconductor Corporation Apparatus, method, and computer program to reduce distortion of scanner restarts
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8119101B2 (en) * 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US6213976B1 (en) 1999-07-22 2001-04-10 Advanced Research And Technology Institute, Inc. Brachytherapy guide catheter
US6782289B1 (en) 1999-10-08 2004-08-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and apparatus for characterizing lesions in blood vessels and other body lumens
DE19957065B4 (de) * 1999-11-26 2005-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Screening-Verfahren für Arzneistoffe
US7166719B2 (en) 2002-06-27 2007-01-23 Health Research, Inc. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
US7897140B2 (en) * 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US7328058B2 (en) 2000-01-04 2008-02-05 Gamma Medica-Ideas, Inc. Intravascular imaging detector
US8909325B2 (en) * 2000-08-21 2014-12-09 Biosensors International Group, Ltd. Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures
WO2004042546A1 (en) * 2002-11-04 2004-05-21 V-Target Technologies Ltd. Apparatus and methods for imaging and attenuation correction
US8036731B2 (en) * 2001-01-22 2011-10-11 Spectrum Dynamics Llc Ingestible pill for diagnosing a gastrointestinal tract
US8489176B1 (en) 2000-08-21 2013-07-16 Spectrum Dynamics Llc Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures
US8565860B2 (en) * 2000-08-21 2013-10-22 Biosensors International Group, Ltd. Radioactive emission detector equipped with a position tracking system
US7826889B2 (en) * 2000-08-21 2010-11-02 Spectrum Dynamics Llc Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures
IL157007A0 (en) * 2001-01-22 2004-02-08 Target Technologies Ltd V Ingestible device
AU2002252105A1 (en) * 2001-02-21 2002-09-12 Imetrx, Inc. Methods and systems which use annexin for bioprofiling body lumen
EP1372741B1 (de) * 2001-03-30 2006-08-09 University of Massachusetts Morpholinobildgebung und therapie
JP2005502618A (ja) * 2001-06-04 2005-01-27 ザ・ジェネラル・ホスピタル・コーポレイション 光力学的化合物を用いて脆弱なプラークを検出および治療する方法
US20030031627A1 (en) * 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
US7053188B2 (en) 2002-02-22 2006-05-30 Purdue Research Foundation Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
IL148921A0 (en) 2002-03-26 2002-09-12 Peptor Ltd Photo active backbone cyclized somatostatin analogs for optical imaging and photodynamic therapy
ES2524767T3 (es) 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
AU2003249742A1 (en) * 2002-07-02 2004-01-23 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
JP5138867B2 (ja) 2002-08-01 2013-02-06 イミューノメディクス、インコーポレイテッド α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
AT413487B (de) * 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US20040116807A1 (en) * 2002-10-17 2004-06-17 Roni Amrami Blood vessels wall imaging catheter
WO2004039233A2 (en) * 2002-10-31 2004-05-13 Given Imaging Ltd. System and method for in vivo detection of h. pylori
US20040204646A1 (en) * 2002-11-04 2004-10-14 V-Target Technologies Ltd. Intracorporeal-imaging head
EP1565107A4 (de) * 2002-11-14 2008-03-05 Ethicon Endo Surgery Inc Verfahren und geräte zum nachweis von gewebezellen
AU2003297099A1 (en) * 2002-12-12 2004-06-30 Manoa Medical, Inc. Percutaneous removal of sentinel lymph node using contrast imaging for identification
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
MXPA05008222A (es) 2003-01-31 2005-10-05 Immunomedics Inc Metodos y composiciones para administrar agentes terapeuticos y de diagnostico.
US20040260182A1 (en) * 2003-06-23 2004-12-23 Zuluaga Andres F. Intraluminal spectroscope with wall contacting probe
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
EP1660519B1 (de) * 2003-07-29 2014-05-14 Immunomedics, Inc. Konjugate von 2-[18F]Fluor-2-desoxy-D-glucose und einem Peptid-Molekül
WO2005014618A2 (en) * 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US6949072B2 (en) * 2003-09-22 2005-09-27 Infraredx, Inc. Devices for vulnerable plaque detection
US7651506B2 (en) * 2003-10-02 2010-01-26 University Of Florida Research Foundation, Inc. Frameless stereotactic guidance of medical procedures
US8571881B2 (en) 2004-11-09 2013-10-29 Spectrum Dynamics, Llc Radiopharmaceutical dispensing, administration, and imaging
US8586932B2 (en) * 2004-11-09 2013-11-19 Spectrum Dynamics Llc System and method for radioactive emission measurement
US9040016B2 (en) * 2004-01-13 2015-05-26 Biosensors International Group, Ltd. Diagnostic kit and methods for radioimaging myocardial perfusion
US10964075B2 (en) 2004-01-13 2021-03-30 Spectrum Dynamics Llc Gating with anatomically varying durations
WO2007054935A2 (en) * 2005-11-09 2007-05-18 Spectrum Dynamics Llc Dynamic spect camera
US7968851B2 (en) * 2004-01-13 2011-06-28 Spectrum Dynamics Llc Dynamic spect camera
CN1981210A (zh) * 2004-01-13 2007-06-13 光谱动力学有限责任公司 多维图像重构
US9470801B2 (en) * 2004-01-13 2016-10-18 Spectrum Dynamics Llc Gating with anatomically varying durations
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8280124B2 (en) 2004-06-01 2012-10-02 Spectrum Dynamics Llc Methods of view selection for radioactive emission measurements
EP1778957A4 (de) * 2004-06-01 2015-12-23 Biosensors Int Group Ltd Optimierung der messung radioaktiver strahlung an besonderen körperstrukturen
US7938775B2 (en) * 2004-06-28 2011-05-10 Given Imaging, Ltd. Device, system, and method for in-vivo analysis
US8423125B2 (en) 2004-11-09 2013-04-16 Spectrum Dynamics Llc Radioimaging
US10136865B2 (en) 2004-11-09 2018-11-27 Spectrum Dynamics Medical Limited Radioimaging using low dose isotope
US9316743B2 (en) 2004-11-09 2016-04-19 Biosensors International Group, Ltd. System and method for radioactive emission measurement
US8615405B2 (en) 2004-11-09 2013-12-24 Biosensors International Group, Ltd. Imaging system customization using data from radiopharmaceutical-associated data carrier
US8606349B2 (en) * 2004-11-09 2013-12-10 Biosensors International Group, Ltd. Radioimaging using low dose isotope
WO2008059489A2 (en) 2006-11-13 2008-05-22 Spectrum Dynamics Llc Radioimaging applications of and novel formulations of teboroxime
US20080260637A1 (en) * 2004-11-17 2008-10-23 Dalia Dickman Methods of Detecting Prostate Cancer
US7872235B2 (en) 2005-01-13 2011-01-18 Spectrum Dynamics Llc Multi-dimensional image reconstruction and analysis for expert-system diagnosis
ES2665422T3 (es) 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20090216082A1 (en) * 2005-04-01 2009-08-27 Elisha Rabinovitz Device, System and Method for In Vivo Magnetic Immunoassay Analysis
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US20130039861A1 (en) * 2005-04-06 2013-02-14 Immunomedics, Inc. Dye Conjugated Peptides for Fluorescent Imaging
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8837793B2 (en) 2005-07-19 2014-09-16 Biosensors International Group, Ltd. Reconstruction stabilizer and active vision
US8644910B2 (en) * 2005-07-19 2014-02-04 Biosensors International Group, Ltd. Imaging protocols
US7450241B2 (en) * 2005-09-30 2008-11-11 Infraredx, Inc. Detecting vulnerable plaque
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
US8204500B2 (en) 2005-12-28 2012-06-19 Starhome Gmbh Optimal voicemail deposit for roaming cellular telephony
US8894974B2 (en) * 2006-05-11 2014-11-25 Spectrum Dynamics Llc Radiopharmaceuticals for diagnosis and therapy
US8140141B2 (en) * 2006-05-17 2012-03-20 University Of Utah Research Foundation Devices and methods for fluorescent inspection and/or removal of material in a sample
US7601966B2 (en) 2006-06-28 2009-10-13 Spectrum Dynamics Llc Imaging techniques for reducing blind spots
JP2008111824A (ja) * 2006-09-01 2008-05-15 Nox Technologies Inc 腫瘍特異的ｔＮＯＸアイソフォーム及び方法
WO2008075362A2 (en) 2006-12-20 2008-06-26 Spectrum Dynamics Llc A method, a system, and an apparatus for using and processing multidimensional data
US8521253B2 (en) * 2007-10-29 2013-08-27 Spectrum Dynamics Llc Prostate imaging
WO2009057774A1 (ja) 2007-10-31 2009-05-07 Olympus Corporation 薬液投与システムおよび薬液投与用カニューラ
EP2677319B1 (de) 2008-07-09 2015-12-30 The Institute for Ethnomedicine Antikörper zum Nachweis von neurotoxischen Aminosäuren, die mit neurologischen Krankheiten assoziiert sind
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
US8338788B2 (en) 2009-07-29 2012-12-25 Spectrum Dynamics Llc Method and system of optimized volumetric imaging
EP2478110B1 (de) 2009-09-16 2016-01-06 Immunomedics, Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
EP2523680A4 (de) * 2010-01-11 2013-06-19 Ct Molecular Med & Immunology Verstärkte zytotoxizität von antikörpern gegen cd74 und hla-dr mit interferon-gamma
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
CN104619350A (zh) 2012-06-14 2015-05-13 Ambrx公司 结合到核受体配体多肽的抗psma抗体
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
WO2014055253A1 (en) * 2012-10-04 2014-04-10 The General Hospital Corporation Methods of synthesizing and using peg-like fluorochromes
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US20240139324A1 (en) 2012-12-13 2024-05-02 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US20140271453A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Methods for the early detection of lung cancer
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2015042529A2 (en) 2013-09-20 2015-03-26 The Regents Of The University Of California Methods, systems, and devices for imaging microscopic tumors
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
AU2017257254B2 (en) 2016-04-27 2022-02-24 Immunomedics, Inc. Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
EP3600283A4 (de) 2017-03-27 2020-12-16 Immunomedics, Inc. Behandlung von trop-2-exprimierendem triple-negativem brustkrebs mit sacituzumab govitecan und einem rad51-hemmer
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
EP3630046B1 (de) 2017-05-30 2024-12-25 The Board of Regents of the University of Oklahoma Anti-doublecortin-like-kinase-1-antikörper und anwendungsverfahren
US20190388702A1 (en) * 2018-06-20 2019-12-26 Olympus Corporation Tumor treatment method
US11625825B2 (en) 2019-01-30 2023-04-11 Covidien Lp Method for displaying tumor location within endoscopic images
EP3888744A1 (de) * 2020-04-02 2021-10-06 RaySearch Laboratories AB Computerimplementiertes verfahren zur planung einer strahlentherapiebehandlung, computerprogrammprodukt und computersystem zur durchführung des verfahrens
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体
US12043671B2 (en) 2021-06-16 2024-07-23 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4782840A (en) * 1984-03-02 1988-11-08 Neoprobe Corporation Method for locating, differentiating, and removing neoplasms
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy

Also Published As

Publication number Publication date
WO1993021940A1 (en) 1993-11-11
DE69329112D1 (de) 2000-08-31
EP0643583A4 (de) 1996-05-08
US5716595A (en) 1998-02-10
EP0643583B1 (de) 2000-07-26
EP0643583A1 (de) 1995-03-22
JPH08500335A (ja) 1996-01-16
CA2133580A1 (en) 1993-11-11
DE69329112T2 (de) 2000-12-14

Similar Documents

Publication Publication Date Title
DE69329112D1 (de) Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren
WO1994004702A3 (en) Improved detection and therapy of lesions with biotin/avidin conjugates
DE60023706D1 (de) Diagnose und behandlung neurorektodermaler tumore
MY121548A (en) Compounds and methods for the treatment of cancer
ES2090131T3 (es) Solucion antineoplasica y procedimiento para el tratamiento de neoplasmas.
EA200000994A1 (ru) Применение кабэрголина при лечении синдрома усталых ног
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
TR200002243T2 (tr) Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
NO942719L (no) Metallkomplekser av vannlöselige texapyriner
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
BG100194A (bg) Трициклополиазамакроциклофосфонови киселини,техни производни и комплекси и използването им като контрастни средства
ES2020011A6 (es) Metodo de sintesis de composiciones que comprenden al menos un butano fenolico.
DE69731652D1 (de) Verfahren zur behandlung von endothelialen verletzungen
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
NO994330D0 (no) Metode for behandling av en tumor
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
SE9103837D0 (sv) Fluorescensdiagnostik av cancer utnyttjande delta-aminolevulinsyra
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
IL101675A0 (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
AU2525488A (en) Use of metalloporphyrins to reverse the toxic effect of tumor therapy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties